Peripheral Artery Disease (Claudication, Investigational)
Highly investigational adjunct for intermittent claudication; ABI must be assessed first; critical limb ischemia is an absolute contraindication.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for peripheral artery disease. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for PAD is highly investigational.
- What evidence exists?
- Tier C (highly investigational). Only a few single-patient case reports were identified, including two in which gangrene or new ulcers followed leech therapy in patients with severe or undiagnosed arterial disease; there are no randomized controlled trials and no data on amputation, MI, or stroke prevention. A medical book (Michalsen and colleagues, 2007) also passes on patients’ own reports about intermittent claudication after leeches were placed for other problems, but it names no study, and such reports cannot show that leeches help (see “What the books describe” below). Evidence-based PAD care per AHA/ACC 2016 guidelines includes smoking cessation, statin therapy, antiplatelet medication (aspirin or clopidogrel), structured supervised exercise (the strongest evidence for claudication), and revascularization (angioplasty / bypass) for lifestyle-limiting disease or critical limb ischemia. Leech therapy on a leg with poor arterial flow can cause tissue breakdown.
- Main risks
- Tissue breakdown, non-healing wound, or gangrene if applied to a limb with low ABI (under 0.6) — this is the dominant risk
- Bleeding from bite sites for 6 to 24 hours after detachment
- Local skin infection or, rarely, Aeromonas infection
- Worsening anemia from cumulative blood loss
- Allergic reaction to leech saliva (uncommon)
- Bleeding interaction with antiplatelet medications (aspirin, clopidogrel) — usually required for PAD
- Delay or replacement of evidence-based therapy with risk of amputation, MI, or stroke
- Who should not consider this
- Patients with ABI under 0.6 (critical limb ischemia)
- Patients on anticoagulants (aspirin and clopidogrel, alone or together, are not a contraindication by themselves: tell your doctor, who starts with fewer leeches)
- Patients with a diabetic foot ulcer or active gangrene
- Patients within 6 weeks of vascular intervention (angioplasty, stenting, bypass)
- Patients with rest pain or non-healing wounds (urgent vascular surgery indication)
- Patients with active infection, hemophilia, or anemia
- What to ask your clinician
- What is my ankle-brachial index (ABI) and toe-brachial index, and what is my Rutherford / Fontaine class?
- Am I on a statin and appropriate antiplatelet therapy?
- Have I tried supervised exercise therapy — the highest-evidence intervention for claudication?
- Am I a candidate for revascularization (angioplasty, stent, bypass)?
- What is my vascular surgery team's opinion on adjunctive complementary therapy?
- If antiplatelet must continue, is leech therapy compatible at all?
- What is the practitioner's experience and Aeromonas-prevention plan?
- When to seek urgent care
- Sudden severe leg pain, coldness, pallor, or pulselessness (acute limb ischemia — call 911)
- Rest pain that interferes with sleep, or a non-healing leg or foot wound
- New gangrene, blackening, or ulceration
- Chest pain, pressure, or shortness of breath
- Sudden weakness, slurred speech, facial droop, or vision loss
- Bleeding from a bite site lasting more than 24 to 48 hours, fever, spreading redness, or pus
- Hives, throat tightness, or breathing difficulty
What this does NOT mean
- This is not FDA-cleared for peripheral artery disease.
- Small uncontrolled reports do NOT establish efficacy on walking distance vs. supervised exercise or on cardiovascular outcomes.
- Mechanism rationale (microvascular flow) does NOT fix proximal arterial stenosis.
- Leech therapy is NEVER a substitute for supervised exercise, statin / antiplatelet therapy, or revascularization when indicated.
- Critical limb ischemia requires urgent vascular surgical evaluation, NOT complementary therapy.
Safety cross-references
Clinical Profile
- Category
- Cardiovascular
- ICD-10
- I70.211, I70.212, I70.213, I73.9
- Safety tier
- High
Evidence Summary
Peripheral artery disease management follows AHA/ACC guidelines: smoking cessation, statin and antiplatelet therapy, supervised exercise, and revascularization for lifestyle-limiting claudication or critical limb ischemia. No controlled trial or case series of leech therapy for PAD or claudication was identified in PubMed, Europe PMC, ClinicalTrials.gov or the Baskova and Isakhanyan 2004 monograph. The journal literature found consists of single-patient reports: one man with critical limb ischemia who self-treated with leeches and reported less pain, burning and numbness (Afify 2021); two Unani and Ayurvedic reports of ischemic finger or toe lesions that improved or healed (Ilyas 2020; Kapadiya 2025, a combined regimen); and two reports of harm, new ulcers and gangrene after leeches in an 84-year-old man with severe PAD (Uzun 2014) and gangrene, amputation and death in a man with undiagnosed arterial occlusive disease (Ostovar 2025). The 2007 book by Michalsen et al. additionally relays patients’ own reports that claudication lessened after leeches were applied for other conditions, without naming any study (see “What the books describe” below). Use for this indication is investigational. Critical safety: leech application to a limb with an ankle-brachial index <0.6 risks tissue breakdown and gangrene, and most PAD patients require antiplatelet therapy, which is an exclusion for leech application.
What the books describe
Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.
- Baskova and Isakhanyan do not write about obliterating diseases of the leg arteries (with intermittent claudication): they name atherosclerosis in general terms — the vessels of the lower limbs are mentioned among the vessels affected, while the list of indications has “Atherosclerosis, atherosclerotic cardiosclerosis, sclerosis of the aorta”, without the leg arteries[B1].
- Flecken and Michalsen (chapter on indications) write that peripheral occlusive arterial disease is one of the central manifestations of arteriosclerosis, that hirudotherapy is unlikely to produce significant improvement of the vascular lesions underlying it, and that the transient effects on the viscosity and flow properties of the blood appear minor compared with established drug treatment options[B3].
- Still, in their words, patients report time and again that intermittent claudication lessened after leeches: they could walk longer distances and/or the symptoms were weaker — when leeches were applied to peripheral areas for another reason, for example for gonarthrosis or varicose veins; the book gives this as patients’ reports, no studies are named, and the authors consider that such observations may justify attempts with leeches in cases where other treatments have failed[B3].
- They state that hirudotherapy in this disease should be carried out only in the initial stages (I–II by the classification that the book calls Fontane) and should never be used in gangrene[B3].
- The therapist, they warn, must beware of concomitant medications — clopidogrel or phenprocoumon (Marcumar), which are frequently prescribed in this disease; Flecken and Michalsen, in the chapter on contraindications, call the use of Marcumar, warfarin, heparin or heparinoids an absolute contraindication, and do not regard aspirin and clopidogrel as a ban in themselves, but with them the number of leeches at the first session should be reduced[B3].
- Flecken and Michalsen also warn that the normally harmless leech bite can lead to local complications in patients with diseases in which wound healing is impaired (for example, diabetes mellitus), and Graf, in the chapter on the leech’s bacterial flora, writes that if the blood supply to the application site is impaired, the risk of wound infection is increased, although, in his words, it can be prevented by prophylactic antibiotics[B3].
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Detailed Trial Entries
1 trial indexed in the ASH RCT Library with full Study Profile, GRADE rating, and clinical implications:
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Active deep vein thrombosis (acute phase)
- Critical limb ischemia (ABI <0.4)
- ABI <0.6 (critical limb ischemia)
- Diabetic foot ulcer or active gangrene
- Recent vascular intervention (<6 weeks)
- Concurrent statin-related rhabdomyolysis
Related Conditions
Chronic Venous Insufficiency (CEAP C3-C5)
Off-label adjunct to compression; the journal evidence is one small open-label randomized trial in varicose veins (n=50) and a 20-patient uncontrolled series; the books describe further reports (see “What the books describe” below).
Raynaud's Syndrome (Primary)
Investigational use for primary Raynaud's phenomenon; the only clinical report is three patients in a 2025 Azerbaijani case series, with no controlled trial.
Deep Vein Thrombosis (Post-Acute Phase Symptoms)
Investigational use for residual symptoms in the post-acute phase of DVT (>6 weeks); contraindicated in acute DVT.
Essential Hypertension (Adjunctive)
Investigational adjunctive use with only non-randomized clinical reports identified; proposed mechanisms are blood-volume removal and hirudin effects on vessels; not a substitute for pharmacotherapy.
References
- [B1]
Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]
Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.
- [B3]
Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy
ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.
The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.